Moderna's mRNA Flu Shot Receives FDA Approval
The U.S. Food and Drug Administration (FDA) has approved Moderna's mRNA-based flu vaccine. The vaccine is authorized for use in adults aged 50 and older.
The U.S. Food and Drug Administration (FDA) has granted approval for Moderna's mRNA-based influenza vaccine. The vaccine, designated mRNA-1010, is now authorized for use in all adults aged 50 and above.
The approval follows a unanimous recommendation from the FDA's advisory committee in June. This decision was based on the vaccine's superior efficacy compared to existing seasonal flu shots and a favorable safety record demonstrated in clinical trials involving nearly 44,000 participants.
While the scientific review process yielded strong support, the path to approval encountered some uncertainty. The vaccine's authorization marks a significant step in leveraging mRNA technology for influenza prevention beyond COVID-19.
Moderna's success with mRNA technology in its COVID-19 vaccines has paved the way for this new influenza vaccine, expanding the company's offerings and its role in public health.